查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566979

獸用疫苗佐劑市場：按類型、給藥途徑、動物類型分類：2024-2033年全球機會分析與產業預測

Veterinary Vaccine Adjuvants Market By Type , By Route of Administration By Type of Animal : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

動物疫苗佐劑市場

2023年獸用疫苗佐劑市值為4億美元，預計2024年至2033年複合年成長率為4.6%，到2033年將達6億美元。

獸用疫苗佐劑是增強動物疫苗免疫反應的重要成分。佐劑是為了增強疫苗產生的免疫反應而添加的生物活性化合物。佐劑作用機轉包括透過增強呈現抗原過程或刺激特定受體來調節免疫途徑。獸用疫苗中最常見的佐劑形式是油乳劑、鋁鹽、脂質體、細菌衍生物和皂素。

寵物飼養趨勢的增加和動物健康支出的激增是動物疫苗佐劑市場的關鍵促進因素。此外，過去幾年動物疾病爆發迅速增加，推動了對獸用疫苗佐劑的需求。最近的趨勢包括在疫苗中添加基於奈米顆粒的佐劑。基於奈米顆粒的佐劑可以控制釋放並封裝抗原，從而防止分解。此外，基於微粒的佐劑和基因佐劑因其高度標靶化的作用機製而受到廣泛歡迎。

然而，一些佐劑可能會引起動物嚴重的全身反應或局部反應原性，引發安全性問題並阻礙市場開拓。此外，疫苗開發的進步正在消除對佐劑的需求，而不會限制疫苗的效力。預計此類技術創新將限制未來幾年的市場開拓。儘管疫苗配方方面有了技術創新，但在產生有效免疫反應方面仍存在一些差距，包括病原體多樣性和疫苗株毒力回應。這些缺點為參與企業獸用疫苗佐劑市場提供了有利的機會。此外，政府的各種動物疫苗接種舉措，例如印度畜牧和酪農部的口蹄疫疫苗接種計劃，正在為市場擴張開闢新的途徑。

按部門審查

獸用疫苗佐劑市場按類型、給藥途徑、動物類型和地區細分。依類型分為明礬&鈣鹽、油乳佐劑、脂質體&古體、奈米顆粒&微粒子等。依給藥途徑分為口服、皮下、肌肉注射等。依動物種類分為家畜動物和伴同性動物。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按類型分類，明礬和鈣鹽細分市場將在 2023 年佔據主導地位。

依給藥途徑，2023年肌肉注射細分市場佔較高市場佔有率。

依動物類型分類，2023 年畜牧業佔較高佔有率。

按地區分類，北美地區 2023 年收益最高。

可以使用此報告進行客製化（需要額外費用和時間表）

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章獸用疫苗佐劑市場：依類型

  • 市場概況
  • 明礬鈣鹽
  • 油乳化助劑
  • 脂質體和古體
  • 奈米顆粒和微米顆粒
  • 其他

第5章獸用疫苗佐劑市場：依給藥途徑

  • 市場概況
  • 口服
  • 皮下給藥
  • 肌肉注射
  • 其他

第6章動物疫苗佐劑市場：依動物類型

  • 市場概況
  • 家畜動物
  • 伴同性動物

第7章獸用疫苗佐劑市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國獸用疫苗佐劑市場
    • 加拿大獸用疫苗佐劑市場
    • 墨西哥獸用疫苗佐劑市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國獸用疫苗佐劑市場
    • 法國獸用疫苗佐劑市場
    • 英國獸用疫苗佐劑市場
    • 義大利獸用疫苗佐劑市場
    • 西班牙獸用疫苗佐劑市場
    • 其他歐洲獸用疫苗佐劑市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本獸用疫苗佐劑市場
    • 中國獸用疫苗佐劑市場
    • 澳洲獸用疫苗佐劑市場
    • 印度獸用疫苗佐劑市場
    • 韓國獸用疫苗佐劑市場
    • 其他亞太獸用疫苗佐劑市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西動物疫苗佐劑市場
    • 沙烏地阿拉伯動物疫苗佐劑市場
    • 南非獸用疫苗佐劑市場
    • 其他拉丁美洲/中東/非洲動物疫苗佐劑市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • SEPPIC
  • SPI Pharma, Inc.
  • Bioveta AS
  • Croda Internation PLC
  • Merck And Co., Inc.
  • MVP Laboratories
  • OZ Biosciences
  • InvivoGen Corporation.
  • Evonik Industries AG
  • Zoetis, Inc.
簡介目錄
Product Code: A324537

Veterinary Vaccine Adjuvants Market

The veterinary vaccine adjuvants market was valued at $0.4 billion in 2023 and is projected to reach $0.6 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.

A veterinary vaccine adjuvant is an element essential to enhance the immune response of the administered vaccine in animals. An adjuvant is a bioactive compound that upon addition elevates the immune response generated by vaccines. The mechanism of action of adjuvants involves enhancement in the antigen presentation process or modulation of immune pathways through the stimulation of certain receptors. The most common forms of adjuvants included in veterinary vaccines are oil emulsions, aluminum salts, liposomes, bacterial derivatives, and saponins.

Increase in the trend of petkeeping and surge in expenditure on their health are the key drivers of the veterinary vaccine adjuvants market. Moreover, the prevalence of diseases in animals has upsurged over the past few years, thereby boosting the demand for veterinary vaccine adjuvants. In recent times, the addition of nanoparticle-based adjuvants in vaccines is trending in the market as they offer controlled release and encapsulate the antigens, thus preventing their degradation. Furthermore, microparticle-based and genetic adjuvants are acquiring prominent traction owing to their highly targeted action mechanism.

However, several adjuvants potentially cause severe systemic reactions and local reactogenicity in animals, raising concerns pertaining to their safety and hampering the development of the market. In addition, advancements in vaccine development are eliminating the requirement of adjuvants, without limiting the efficacy of vaccines. Such innovations are anticipated to restrain the development of the market in upcoming years. Despite the innovations in vaccine formation, several gaps exist in the generation of effective immune response, such as pathogen variability and virulent reversion of vaccine strains. These shortcomings present lucrative opportunities for the players in the veterinary vaccine adjuvant market. Further, the implementation of different veterinary vaccination drives by governments, such as the foot and mouth disease vaccination program by the Department of Animal Husbandry & Dairying in India, open new avenues for market expansion.

Segment Review

The veterinary vaccine adjuvants market is segmented into type, route of administration, type of animal, and region. On the basis of type, the market is divided into alum & calcium salts, oil emulsion adjuvants, liposomes & archaeosomes, nanoparticles & microparticles, and others. By route of administration, it is classified into oral, subcutaneous, intramuscular, and others. As per type of animal, it is bifurcated into livestock animals and companion animals. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the alum & calcium salts segment dominated the market in 2023.

By route of administration, the intramuscular segment accounted for a high market share in 2023.

As per type of animal, the livestock animals segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global veterinary vaccine adjuvants market include SEPPIC, SPI Pharma, Inc., Bioveta AS, Croda Internation PLC, Merck & Co., Inc., MVP Laboratories, OZ Biosciences, InvivoGen Corporation., Evonik Industries AG, and Zoetis, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Alum and Calcium Salts
  • Oil Emulsion Adjuvants
  • Liposomes and Archaeosomes
  • Nanoparticles and Microparticles
  • Others

By Route Of Administration

  • Oral
  • Subcutaneous
  • Intramuscular
  • Others

By Type Of Animal

  • Livestock Animals
  • Companion Animals

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • SEPPIC
    • SPI Pharma, Inc.
    • Bioveta AS
    • Croda Internation PLC
    • Merck & Co., Inc.
    • MVP Laboratories
    • OZ Biosciences
    • InvivoGen Corporation.
    • Evonik Industries AG
    • Zoetis, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Alum And Calcium Salts
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Oil Emulsion Adjuvants
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Liposomes And Archaeosomes
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Nanoparticles And Microparticles
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Route of Administration
  • 5.2. Oral
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Subcutaneous
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Intramuscular
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Others
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Type of Animal
  • 6.2. Livestock Animals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Companion Animals
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: VETERINARY VACCINE ADJUVANTS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Route of Administration
    • 7.2.4. Market Size and Forecast, By Type of Animal
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Veterinary Vaccine Adjuvants Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Route of Administration
      • 7.2.6.3. Market Size and Forecast, By Type of Animal
    • 7.2.7. Canada Veterinary Vaccine Adjuvants Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Route of Administration
      • 7.2.7.3. Market Size and Forecast, By Type of Animal
    • 7.2.8. Mexico Veterinary Vaccine Adjuvants Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Route of Administration
      • 7.2.8.3. Market Size and Forecast, By Type of Animal
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Route of Administration
    • 7.3.4. Market Size and Forecast, By Type of Animal
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Veterinary Vaccine Adjuvants Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Route of Administration
      • 7.3.6.3. Market Size and Forecast, By Type of Animal
    • 7.3.7. France Veterinary Vaccine Adjuvants Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Route of Administration
      • 7.3.7.3. Market Size and Forecast, By Type of Animal
    • 7.3.8. UK Veterinary Vaccine Adjuvants Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Route of Administration
      • 7.3.8.3. Market Size and Forecast, By Type of Animal
    • 7.3.9. Italy Veterinary Vaccine Adjuvants Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Route of Administration
      • 7.3.9.3. Market Size and Forecast, By Type of Animal
    • 7.3.10. Spain Veterinary Vaccine Adjuvants Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Route of Administration
      • 7.3.10.3. Market Size and Forecast, By Type of Animal
    • 7.3.11. Rest of Europe Veterinary Vaccine Adjuvants Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Route of Administration
      • 7.3.11.3. Market Size and Forecast, By Type of Animal
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Route of Administration
    • 7.4.4. Market Size and Forecast, By Type of Animal
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Veterinary Vaccine Adjuvants Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Route of Administration
      • 7.4.6.3. Market Size and Forecast, By Type of Animal
    • 7.4.7. China Veterinary Vaccine Adjuvants Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Route of Administration
      • 7.4.7.3. Market Size and Forecast, By Type of Animal
    • 7.4.8. Australia Veterinary Vaccine Adjuvants Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Route of Administration
      • 7.4.8.3. Market Size and Forecast, By Type of Animal
    • 7.4.9. India Veterinary Vaccine Adjuvants Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Route of Administration
      • 7.4.9.3. Market Size and Forecast, By Type of Animal
    • 7.4.10. South Korea Veterinary Vaccine Adjuvants Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Route of Administration
      • 7.4.10.3. Market Size and Forecast, By Type of Animal
    • 7.4.11. Rest of Asia-Pacific Veterinary Vaccine Adjuvants Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Route of Administration
      • 7.4.11.3. Market Size and Forecast, By Type of Animal
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Route of Administration
    • 7.5.4. Market Size and Forecast, By Type of Animal
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Veterinary Vaccine Adjuvants Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Route of Administration
      • 7.5.6.3. Market Size and Forecast, By Type of Animal
    • 7.5.7. Saudi Arabia Veterinary Vaccine Adjuvants Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Route of Administration
      • 7.5.7.3. Market Size and Forecast, By Type of Animal
    • 7.5.8. South Africa Veterinary Vaccine Adjuvants Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Route of Administration
      • 7.5.8.3. Market Size and Forecast, By Type of Animal
    • 7.5.9. Rest of LAMEA Veterinary Vaccine Adjuvants Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Route of Administration
      • 7.5.9.3. Market Size and Forecast, By Type of Animal

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. SEPPIC
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. SPI Pharma, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Bioveta AS
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Croda Internation PLC
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Merck And Co., Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. MVP Laboratories
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. OZ Biosciences
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. InvivoGen Corporation.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Evonik Industries AG
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Zoetis, Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments